Report of
FNCA FY2019 Workshop on Radiation Oncology

Outline of Workshop

The FNCA 2019 Workshop on Radiation Oncology was held from 28 to 31 October, 2019 in Suzhou, China. The workshop was co-organized by Soochow University, The First Affiliated Hospital of Soochow University, China Atomic Energy Authority (CAEA) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 10 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Korea, Malaysia, Mongolia, the Philippines, Thailand and Vietnam participated in the workshop.
This project carries out some international joint clinical studies in order to establish treatment protocols for uterine cervix cancer, nasopharyngeal cancer and breast cancer, which affect large number of people in FNCA member countries, and finally to improve the technique of radiation oncology in the Asian region.

Opening Ceremony
Prof. Cao Jiaping, Professor/ Director, School of Radiation Medicine and Protection, Soochow University moderated the session.
Prof CHEN Weichang, Vice President of Soochow University welcomed the participants with his remarks.
Mr. WADA Tomoaki, FNCA Coordinator of Japan gave the opening address.
Ms. Tanaka Fumiyo, MEXT gave her remarks and introduces MEXT programs for Asian countries.
Prof. KATO Shingo, the Project Leader of Radiation Oncology Project gave his remarks and introduced the project.

2 special lectures were delivered in the end of the Opening Session.
Dr Zhen Zhang (Director of Department of Radiotherapy, Shanghai Cancer Center Affiliated Fudan University) delivered a lecture entitled "Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer-Shanghai Cancer Center Experience".
Dr. Jiade Lu (Shanghai Proton and Heavy Ion Center) delivered the next speech entitled" The use of Carbon Ion Radiation Technology in the Treatment of Cancer-Experience at the Shanghai Proton and Heavy Ion Center".

Prospective Observational Study of 3D-Image guided brachy therapy for Locally Advanced Cervical Cancer (CERVIX-V)
This is a new protocol for cervical cancers following Cervix-IV which was ended successfully with its publication.
Newly registered clinical data of CERVIX-V was presented by representatives of each participating country with the following number of patients: Bangladesh ( 0 ), China (6, n=3 ), Indonesia ( 7,n=1 ), Japan (5, n=3 ), Kazakhstan ( 4, n=2), Korea ( 0 ), Malaysia ( 6, n=5 ), Mongolia (2,n=2 ), Philippines ( 8, n=4 ), Thailand ( 0 ) and Vietnam ( 0 ). The total number of the patients was (38,n=20).

Discussion on CERVIX-V followed. Follow-up will be patterned to Cervix-IV at six months. Detailed discussion on follow-up method and timing was made and it was presented by Dr. OKONOGI at a later session. The change will be incorporated in the protocol and will be communicated to the member countries at a later date.

QA/QC for 3D-IGBT
This activity aims to put in place reliable dosimetry in the institutes among the member countries for effective joint clinical studies. The audits in QA/QC of dosimetry measurement and radiation calibration have been conducted, which is for the reliable radiotherapy.
Along with the initiation of CERVIX-V, this QA/QC activity also focuses on the brachytherapy.

First, the current status of 3D-IGBT in China was presented by a local medical physicist.3 aspects for 3D-IGBTwere introduced: the overview of infrastructure, the content of QA-QC and the relevant development and research in China.

Japan introduced the methodology of audit for 3D-IGBT and introduced phantom jigs and also the audit programs for 3D-IGBT.

Japan also reported on the results of on-site audit for 3D-IGBT of 2 institutes (Saitama Medical University International Medical Center, Japan & Korea Institute of Radiological & Medical Sciences, Korea).

Phase II Study of Neoadjuvant Chemotherapy with Concurrent Chemoradiotherapy (CCRT) for Nasopharyngeal Carcinoma (NPC-III)
A total 120 patients have been registered in this protocol at the time of this workshop. Out of 120 cases, 10 cases were newly registered this year. The 120 cases were consisted of Bangladesh ( 1 ), China ( 9 ), Indonesia ( 12 ), Japan ( 0 ), Kazakhstan ( 0 ), Korea ( 0 ), Malaysia ( 31 ), Mongolia ( 0 ), Philippines ( 7 ) Thailand ( 0 ) and Vietnam ( 60 ). New cases: 10.

Registration for NPC III has been completed. Median age was 46 years. Median overall treatment time of radiotherapy was 53 days (range 44 - 232 days). Radiotherapy treatment interruption of more than 14 days occurred in 22% of patients mainly due to machine breakdown, re-planning and toxicities.

All patients had 2-3 cycles of neoadjuvant chemotherapy with a compliance rate of 100%, while concurrent chemotherapy had 74% compliance rate for 4 cycles or more.

In the neoadjuvant phase, grade 3/4 hematological toxicities occurred in leucopenia 3%, neutropenia 10%, anemia 2% of patients and non-hematological toxicities like nausea/vomiting 5%, fatigue 1%. During the concurrent phase, grade 3/4 hematological toxicities occurred in leucopenia 14%, neutropenia 9%, anemia 4%, thrombocytopenia 2% of patients and non-hematological toxicities like dermatitis 11%, mucositis 20%, dry mouth 9%, nausea/vomiting 7%, weight loss 14 %, fatigue 11%. Late toxicities of grade 3 occurred in 10% of patients, mainly salivary gland and subcutaneous tissue toxicities.

The efficacy results showed a 3-year survival outcomes: OS was 76% (NPC-I 57%), loco-regional failure was 25% (NPC-I 14%), distant metastasis free rate (DMF) was 83% (NPC-I 69%) and PFS was 72% (NPC-I 63%). This is matched with NPC-I results (CCRT and adjuvant chemotherapy) where there were significant differences on: lower loco-regional control, reduced distant metastases, and better overall survival in NPC-III (induction chemotherapy and CCRT).

Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT)/BREAST-I)
In this session, a protocol PMRT/BREAST-I was reviewed and the following numbers were reported. Bangladesh (84), China (13), Indonesia (2), Japan (14), Kazakhstan (20), Korea (0), Malaysia (0), Mongolia (26), Philippines (18), Thailand (0) and Vietnam (0).
The total number of PMRT patients was 221.Evaluable number of patients was also 221.
From 2013-2019 (78 months), 221 patients were registered and completed the protocol treatment. Enrollment is now completed.

Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Whole Breast Irradiation / BREAST-I)
In this session, a protocol WBI/BREAST-I was reviewed and the following numbers were reported. Bangladesh ( 31 ), China ( 6 ), Indonesia ( 16 ), Japan ( 136 ), Kazakhstan ( 14 ), Korea ( 9 ), Malaysia ( 0 ), Mongolia ( 3 ), Philippines ( 0 ), Thailand ( 14 ) and Vietnam ( 0 ). Total number of WBI patients was 229. (229 patients / 230 breast lesions).
The summary of the clinical data is as follows.
The clinical stages: 0 (37), 1A (121), 1B (3), 2A (49), 2B (20). The acute adverse effects of skin G0 (8%), G1 (80%), G2 (10%), G3 (2%); subcutaneous tissue G0 (90%), G1 (10%). The late adverse effects of skin G0 (80%), G1 (20%); subcutaneous tissue G0 (90%), G1 (10%); breast G0 (92%), G1 (8%); lung G0 (98%), G1 (2%). In summary, there was no higher than grade 2 toxicity in this study. The cosmetic outcome were excellent (107), good (1) and poor (3) in patients with more than 3 years follow-up. With the median follow-up of 35 months, there were 1 loco-regional recurrence, 3 distant metastases, 2 breast cancer deaths and 2 intercurrent deaths.

An open discussion on the clinical data followed.
The grade 3 skin toxicity in one institute was acknowledged and treatment process and toxicity grading will be reviewed.

Enrollment completed in 2018. Some data correction will be needed before manuscript submission. This report will include early results within 3-year follow-up. Long term follow-up is still needed to confirm the final results. We are expected to follow-up the patients every six months for 5 years and yearly thereafter.

Review of Project Activities (JFY 2017-2019)
Japan presented the review of the project activities for the last 3 years. The summaries are described in the "Final Report of the Project". In brief,

1) Phase II study "Cervix-IV"
The treatment outcomes of concurrent cisplatin chemotherapy and prophylactic extended-field radiotherapy for locally advanced cervical cancer was reported. Between 2007 and 2016, 106 patients were enrolled in the study. The results were assessed in 2018. The incidence of acute grade 3 hematological toxicity was 21%, and that of late grade 3 gastrointestinal toxicity was 3%. The 2-year local control, progression-free survival, and overall survival rates for all patients were 96%, 78%, and 90%, respectively. The results indicated that concurrent chemotherapy and prophylactic extended-field radiotherapy is feasible and effective for patients with locally advanced cervical cancer in East and Southeast Asia. The results of the study was published in the International medical journal in 2019.

2) 3D image-guided brachytherapy (3D-IGBT) for cervical cancer
A preliminary survey was carried out on 3D image-guided brachytherapy (3D-IGBT) for cervical cancer from 2014 to 2016. A prospective observational study on 3D-IGBT for locally advanced cervical cancer has been initiated in 2018. The feasibility, safety, and efficacy of the treatment are evaluated. Hands-on training session was held in Dhaka during the FNCA WS in 2018 because training of medical personnel is very important to implement 3D-IGBT in FNCA member countries. Many local doctors, medical physicists and FNCA delegates participated in the training session. Training session at the WS will be continued as one of the main activities of the project.

3) Nasopharyngeal Carcinoma
A phase II clinical study "NPC-III" was conducted to evaluate the safety and efficacy of the combination of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Between 2010 and 2019, a total of 120 patients were enrolled in the study. Tentative results showed a comparable overall survival rate compared to NPC-I trial which utilized adjuvant chemotherapy. Toxicity of the protocol treatment was considered tolerable.

4) Breast Cancer

5) Physical QA/QC of Radiotherapy
A survey on quality assurance (QA) and quality control (QC) of external beam radiotherapy was carried out using glass dosimeters among the facilities of the FNCA MSs with the dose audit of 16 facilities (46 beams) in 11 countries. The results of the survey were published in the international medical journal in 2017.
Regarding QA/QC of 3D-IGBT, a new sophisticated phantom for the audit of 3D-IGBT has been designed and manufactured. Then, on-site audits have been conducted at the participating institutes from 2019.

Future Plans (JFY 2020-2022)
The future activities in the next 3 years were proposed by Japan, as follows.

• Continuing all projects going on in the present for over 3 years (2020-2023) because long follow-up for the patients treated under current protocols is very important to determine the long term efficacy of the treatment protocols.
• A new program on palliative radiotherapy for bone metastases in the FNCA member countries. Participants discussed on the implementation of the project.

From Thailand, Dr. Kullathorn THEPHAMONGKHOL Lecturer, Siriraj Hospital, Mahidol University proposed a project on brain metastases. It was agreed that a preliminary survey will be conducted on bone and brain metastases. Questionnaires will be sent to the FNCA member countries.

Additionally, a collaboration with IAEA RCA project on palliative radiotherapy was proposed by Japan.

The next workshop is tentatively scheduled to be held in Mongolia on September 22-25, 2020.

Drafting the Workshop Minutes
The draft of the minutes was submitted by rapporteurs, discussed and then amended. It will be circulated after the workshop and finalized.

Technical Visit to the First Affiliated Hospital of Soochow University
On the 3rd day, the WS participants conducted a Technical Visit to the First Affiliated Hospital of Soochow University.

Open Lecture
Open Lecture was held at the First Affiliated Hospital of Soochow University.
There were 4 lectures on the themes of 1) Overview and Introduction of FNCA, 2) Stereotactic Body Radiation Therapy (SBRT) for Lung Cancer, 3) Overview of Present Status of Cancer Epidemiology and Radiotherapy in China, 4) Particle Beam Therapy. In addition, "Special Lecture on 3D-IGBT for Cervical Cancer" was delivered. The lecture was composed of 3 parts. The overview of 3D-IGBT was introduced, case studies were presented and 3D-IGBT treatment method was instructed to the audience.

Prof. KATO Shingo made his comments and concluded the Open Lecture with his closing remarks.

Technical Visit to Shanghai Proton and Heavy Ion Center, Shanghai Cancer Center affiliated Fudan University
On the 4th day, the WS participants moved to Shanghai and visited Shanghai Proton and Heavy Ion Center and also Shanghai Cancer Center affiliated Fudan University.

Minutes of
FNCA 2019 Workshop on Radiation Oncology Project

(1) Following the agreement at the 20^th Forum for Nuclear Cooperation in Asia (FNCA) Coordinators Meeting, the FNCA FY2019 Workshop on Radiation Oncology was held from October 28th to 31st 2019, in Suzhou, China. The meeting was co-organized by Soochow University, The First Affiliated Hospital of Soochow University, China Atomic Energy Authority (CAEA) and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT). Representatives from 10 FNCA member countries, namely Bangladesh, China, Indonesia, Japan, Korea, Malaysia, Mongolia, Philippines, Thailand and Vietnam participated in the workshop.

Opening Ceremony
(2) Prof. Jianping CAO, Professor/ Director, School of Radiation Medicine and Protection, Soochow University moderated the session.

Prof. Weichang CHEN, Vice President of Soochow University welcomed the participants with his remarks.

Mr. WADA Tomoaki, FNCA Coordinator of Japan gave the opening address.

Ms. TANAKA Fumiyo, MEXT gave her remarks and introduced MEXT programs for Asian countries.

Prof. KATO Shingo, the Project Leader of Radiation Oncology Project gave his remarks and introduced the project.

(3) Introduction of individual participants followed.

(4) The agenda was adopted and chairpersons and rapporteurs were selected.

(5) Dr. Zhen ZHANG, Director of Department of Radiotherapy, Shanghai Cancer Center Affiliated Fudan University gave a special lecture entitled "Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer - Shanghai Cancer Center Experience".

(6) Dr. Jiade LU, Shanghai Proton and Heavy Ion Center gave another lecture entitled "The Use of Carbon Ion Radiation Technology in the Treatment of Cancer - Experience at the Shanghai Proton and Heavy Ion Center".

Session 1: Prospective Observational Study of 3D-Image Guided Brachytherapy for Locally Advanced Cervical Cancer (CERVIX-V)
(7) Dr. OKONOGI Noriyuki, Chief Physician, Clinical Research Group of Pelvic tumor, Department of Charged Particle Therapy Research, National institute of Radiological Sciences(NIRS) Quantum Medical Science Directorate National Institutes for Quantum and Radiological Science and Technology (QST) presented the protocol of Cervix-V.

(8) Newly registered clinical data of CERVIX-V was presented by representatives of each participating country with the following number of patients: Bangladesh (0), China (6, n=3), Indonesia (7, n=1), Japan (5, n=3), Kazakhstan (4, n=2), Korea (0), Malaysia (6, n=5), Mongolia (2, n=2), Philippines (8, n=4), Thailand (0) and Vietnam (0). The total number of the patients was (38, n=20).

(9) Discussion on CERVIX-V followed. Follow-up will be patterned to Cervix-IV at six months. Detailed discussion on follow-up method and timing was made and it was presented by Dr. OKONOGI at a later session. The change will be incorporated in the protocol and will be communicated to the member countries at a later date.

Session 2: QA/QC for 3D-IGBT
(10) Dr. Jie NI, Medical Physicist of the First Affiliated Hospital of Soochow University spoke on Current Status of 3D-IGBT in China. She briefly introduced three aspects for 3D-IGBT: the overview of infrastructure, the content of QA/QC, and the relevant development and research in China.

(11) Mr. NAKAJI Taku, Technical Staff, Quality Control Section, QST Hospital, Quantum Medical Science Directorate, QST introduced the methodology of audit for 3D-IGBT. He introduced the developed phantom jigs and the audit program for 3D-IGBT.

(12) Dr. MIZUNO Hideyuki, Principal Researcher, Quality Control Section,
QST hospital of Quantum Medical Science Directorate QST, reported on the results of on-site audit for 3D-IGBT of the two institutions in Saitama Medical University International Medical Center (Japan) and Korea Institute of Radiological & Medical Sciences (Korea) this year.

Session 3: Phase II Study of Neoadjuvant Chemotherapy with Concurrent Chemoradiotherapy (CCRT) for Nasopharyngeal Carcinoma (NPC-III)
(13) Dr. MAKISHIMA Hirokazu, Attending Physician, Clinical Research Group of Pelvic Tumor Department of Charged Particle Therapy Research NIRS, Quantum Medical Science Directorate, QST introduced the protocol of NPC-III, a Phase II Study of Neoadjuvant Chemotherapy with CCRT for Nasopharyngeal Carcinoma (NPC). Recent clinical data was presented by representatives of each participating country.

An update on the clinical data of NPC-III was presented by representatives of each participating country with the following number of patients: Bangladesh ( 1 ), China ( 9 ), Indonesia ( 12 ), Japan ( 0 ), Kazakhstan ( 0 ), Korea ( 0 ), Malaysia ( 31 ), Mongolia ( 0 ), Philippines ( 7 ) Thailand ( 0 ) and Vietnam ( 60 ). The total number of the patients was (120) and new cases were ( 10 ).

(14) Dr. MAKISHIMA then presented the summary of the follow-up data. The total number of the patients enrolled to this study were 120. Registration for NPC III has been completed. Median age was 46 years. Median overall treatment time of radiotherapy was 53 days (range 44 - 232 days). Radiotherapy treatment interruption of more than 14 days occurred in 22% of patients mainly due to machine breakdown, re-planning and toxicities.

All patients had 2-3 cycles of neoadjuvant chemotherapy with a compliance rate of 100%, while concurrent chemotherapy had 74% compliance rate for 4 cycles or more.

(15) In the neoadjuvant phase, grade 3/4 hematological toxicities occurred in leucopenia 3%, neutropenia 10%, anemia 2% of patients and non-hematological toxicities like nausea/vomiting 5%, fatigue 1%. During the concurrent phase, grade 3/4 hematological toxicities occurred in leucopenia 14%, neutropenia 9%, anemia 4%, thrombocytopenia 2% of patients and non-hematological toxicities like dermatitis 11%, mucositis 20%, dry mouth 9%, nausea/vomiting 7%, weight loss 14 %, fatigue 11%. Late toxicities of grade 3 occurred in 10% of patients, mainly salivary gland and subcutaneous tissue toxicities.

The efficacy results showed a 3-year survival outcomes: OS was 76% (NPC-I 57%), loco-regional failure was 25% (NPC-I 14%), distant metastasis free rate (DMF) was 83% (NPC-I 69%) and PFS was 72% (NPC-I 63%). This is matched with NPC-I results (CCRT and adjuvant chemotherapy) where there were significant differences on: lower loco-regional control, reduced distant metastases, and better overall survival in NPC-III (induction chemotherapy and CCRT).

(16) An open discussion on the clinical data followed.

Session 4: Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Postmastectomy Radiation Therapy (PMRT)/BREAST-I)
(17) Dr. KONO Sawa, Assistant Professor, Department of Radiation Oncology, Tokyo Women's Medical University introduced and reviewed the protocol of PMRT/BREAST-I.

(18) The clinical data of Phase II Study of Postmastectomy Radiation Therapy (PMRT) was presented by representatives of each participating country. The following number of patients were reported: Bangladesh ( 84 ), China ( 13 ), Indonesia ( 0 ), Japan ( 14 ), Kazakhstan ( 20 ), Korea ( 0 ), Malaysia ( 0 ), Mongolia ( 26 ), Philippines ( 18 ), Thailand ( 0 ) and Vietnam ( 46 ). From 2013 to 2019, 221 patients were registered and completed the protocol treatment. Enrollment is now completed.

(19) Prof. KARASAWA Kumiko, Dean of School of Medicine, Professor and Chair, Department of Radiation Oncology, School of Medicine, Tokyo Women's Medical University presented the summary of the PMRT clinical data of breast cancer cases. Overall ( 221 ) patients in HF-PMRT arm were enrolled in 78 months. Evaluable number of patients was ( 221 ).

(20) An open discussion on the clinical data followed.

(21) Patients enrolled from Vietnam have higher grade skin toxicities than other institutions. It was suggested to recheck the patients' photo from follow-up examinations.

Session 5: Phase II Study of Hypofractionated Radiotherapy for Breast Cancer (Whole Breast Irradiation (WBI)/ BREAST-I)
(22) Dr. KONO Sawa introduced and reviewed the protocol of Whole Breast Irradiation (WBI) / BREAST-I.

(23) The clinical data of Phase II Study of WBI was presented by representatives of each participating country. The following numbers were reported: Bangladesh ( 31 ), China ( 6 ), Indonesia ( 16 ), Japan ( 136 ), Kazakhstan ( 14 ), Korea ( 10 ), Malaysia ( 0 ), Mongolia ( 3 ), Philippines ( 0 ), Thailand ( 14 ) and Vietnam ( 0 ). Total number of WBI patients was 229.

(24) Prof. KARASAWA Kumiko presented the summary of the WBI clinical data of breast cancer cases (229 patients / 230 breast lesions). The clinical stages are as follows: 0 (37), 1A (121), 1B (3), 2A (49), 2B (20). The acute adverse effects of skin G0 (8%), G1 (80%), G2 (10%), G3 (2%); subcutaneous tissue G0 (90%), G1 (10%). The late adverse effects of skin G0 (80%), G1 (20%); subcutaneous tissue G0 (90%), G1 (10%); breast G0 (92%), G1 (8%); lung G0 (98%), G1 (2%). In summary, there was no higher than grade 2 toxicity in this study. The cosmetic outcome were excellent (107), good (1) and poor (3) in patients with more than 3 years follow-up. With the median follow-up of 35 months, there were 1 loco-regional recurrence, 3 distant metastases, 2 breast cancer deaths and 2 intercurrent deaths.

(25) An open discussion on the clinical data followed. The grade 3 skin toxicity in one institute was acknowledged and treatment process and toxicity grading will be reviewed.

(26) Enrollment completed in 2018. Some data correction will be needed before manuscript submission. This report will include early results within 3-year follow-up. Long term follow-up is still needed to confirm the final results. We are expected to follow-up the patients every six months for 5 years and yearly thereafter.

Session 6: Review of Project Activities and Future Plan
(27) Prof. KATO Shingo presented the review of the project activities for the last 3 years. The summaries are described in the "Final Report of the Project". In brief,

(28) Prof. KATO also proposed the future activities in the next 3 years as follows.

He proposed to continue all projects going on in the present for over 3 years (2020-2023) because long follow-up for the patients treated under current protocols is very important to determine the long term efficacy of the treatment protocols.

He also proposed new program on palliative radiotherapy for bone metastases in the FNCA member countries and participants discussed on the implementation of the project.

Dr. Kullathorn THEPHAMONGKHOL Lecturer, Siriraj Hospital Mahidol University proposed a project on brain metastases. It was agreed that a preliminary survey will be conducted on bone and brain metastases. Questionnaires will be sent to the FNCA member countries.

Prof. WAKATSUKI Masaru, Professor, Department of Radiology, Jichi Medical University proposed a collaboration with IAEA RCA project on palliative radiotherapy.

(29) The next workshop is tentatively scheduled to be held in Mongolia on September 22-25, 2020.

Session 7: Drafting the Workshop Minutes
Participants reviewed workshop discussion.

(30) The draft of the minutes was submitted by rapporteurs, discussed and amended. The draft of the minutes will be circulated after the workshop and finalized.

(31) Prof. KATO Shingo summarized and commented on the sessions on the 1st and 2nd days. He also expressed expectation towards the next 2 days.

Session 8: Technical Visit 1
(32) Workshop participants conducted a Technical Visit to the First Affiliated Hospital of Soochow University.

Session 9: Open Lecture
(33) The Open Lecture was held at the First Affiliated Hospital of Soochow University.

(34) Dr. Xiaoting XU moderated the session and Prof. Gang CHEN, Vice Director of The First Affiliated Hospital of Soochow University welcomed the audience with his opening remarks.

(35) Mr. WADA Tomoaki gave a lecture about the FNCA. He introduced its overview and spoke about the on-going 7 projects' activities and achievements.

(36) Dr. Wonil JANG, Chief, Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences (KIRAMS) gave a lecture on the Stereotactic Body Radiation Therapy (SBRT) for Lung Cancer.

(37) Dr. Juying ZHOU, Director of the Department of Radiation Oncology of the First Affiliated Hospital of Soochow University delivered a lecture on Overview of Present Status of Cancer Epidemiology and Radiotherapy in China.

(38) Prof. OHNO Tatsuya, Professor and Chairperson, Department of Radiation Oncology, Gunma University Graduate School of Medicine spoke on Particle Beam Therapy.

(39) Lastly, "Special Lecture on 3D-IGBT for Cervical Cancer" was moderated by Prof. Rey H. DE LOS REYES and was delivered by Prof. Masaru WAKATSUKI and Dr. Noriyuki OKONOGI. They introduced the overview of 3D-IGBT, presented case studies and instructed the treatment method.

(40) Prof. KATO Shingo made comments on the Open Lecture.

Session 10: Technical Visit 2
(41) The participants moved to Shanghai and conducted a Technical Visit to Shanghai Proton & Heavy Ion Center.

Session 11: Technical Visit 3
(42) The participants visited Shanghai Cancer Center affiliated Fudan University as well.

Program of
FNCA FY2019 Workshop on Radiation Oncology Project

Day 1 Mon, 28th October 2019 Place: Garden Hotel Suzhou

Day 2 Tue, 29th October 2019 Place: Garden Hotel Suzhou

Day 3 Wed, 30th October 2019 Place: The first Affiliated Hospital of Soochow University

Day 4 Thu, 31st October 2019, Place: Shagnhai Proton & Heavy Ion Center & Fudan University Shanghai Cancer Center

Day 5 Fri, 1st November 2019

Leave from Shanghai